Published in PLoS One on March 08, 2010
Early growth response protein-1 mediates lipotoxicity-associated placental inflammation: role in maternal obesity. Am J Physiol Endocrinol Metab (2013) 0.96
HSP90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-κB pathways. Inflamm Res (2012) 0.95
Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. Oncogene (2013) 0.91
Transcriptional complexity and roles of Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer. Nucleic Acids Res (2014) 0.81
Inflammatory responses in primary muscle cell cultures in Atlantic salmon (Salmo salar). BMC Genomics (2013) 0.81
Differential Expression of the Activator Protein 1 Transcription Factor Regulates Interleukin-1ß Induction of Interleukin 6 in the Developing Enterocyte. PLoS One (2016) 0.80
JUNB is a key transcriptional modulator of macrophage activation. J Immunol (2014) 0.80
Inferring active regulatory networks from gene expression data using a combination of prior knowledge and enrichment analysis. BMC Bioinformatics (2016) 0.79
Chromatin loop organization of the junb locus in mouse dendritic cells. Nucleic Acids Res (2013) 0.76
Human Intervention Study to Assess the Effects of Supplementation with Olive Leaf Extract on Peripheral Blood Mononuclear Cell Gene Expression. Int J Mol Sci (2016) 0.75
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
Toll-like receptors. Annu Rev Immunol (2001) 26.06
AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer (2003) 8.88
Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell (1994) 8.65
LPS/TLR4 signal transduction pathway. Cytokine (2008) 6.60
Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem (1997) 5.14
AP-1 subunits: quarrel and harmony among siblings. J Cell Sci (2004) 5.08
Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol (1997) 5.06
Dendritic cells in a mature age. Nat Rev Immunol (2006) 5.03
Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol (2005) 4.11
Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med (1997) 4.04
Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene (2001) 3.83
A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol (2004) 3.25
When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity (2008) 3.15
Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation. EMBO J (1999) 2.96
Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. J Biol Chem (1997) 2.73
c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem (2000) 2.71
Fos/AP-1 proteins in bone and the immune system. Immunol Rev (2005) 2.58
Transcriptional pausing caused by NELF plays a dual role in regulating immediate-early expression of the junB gene. Mol Cell Biol (2006) 2.40
c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell (2000) 2.35
NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol (2004) 1.96
Transcription factor expression in lipopolysaccharide-activated peripheral-blood-derived mononuclear cells. Proc Natl Acad Sci U S A (2007) 1.63
Deciphering B-ZIP transcription factor interactions in vitro and in vivo. Biochim Biophys Acta (2006) 1.61
Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol (2005) 1.55
Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity (2009) 1.43
Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J Immunol (2008) 1.41
The IkappaB kinase complex and NF-kappaB act as master regulators of lipopolysaccharide-induced gene expression and control subordinate activation of AP-1. Mol Cell Biol (2004) 1.39
Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J Biol Chem (2005) 1.36
CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-kappa B, AP-1, and C/EBP. J Immunol (2003) 1.33
Th2 cell-specific cytokine expression and allergen-induced airway inflammation depend on JunB. EMBO J (2002) 1.31
Cell cycle promoting activity of JunB through cyclin A activation. J Biol Chem (2002) 1.20
Characterization of an activation protein-1-binding site in the murine interleukin-12 p40 promoter. Demonstration of novel functional elements by a reductionist approach. J Biol Chem (2001) 1.17
Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. Mol Cell Biol (2007) 1.16
Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor angiogenesis. EMBO J (2007) 1.13
Turning NF-kappaB and IRFs on and off in DC. Trends Immunol (2008) 1.12
CD40 induces interleukin-6 gene transcription in dendritic cells: regulation by TRAF2, AP-1, NF-kappa B, AND CBF1. J Biol Chem (2002) 1.12
SUMOylation regulates the transcriptional activity of JunB in T lymphocytes. J Immunol (2008) 1.03
An acute phase response factor/NF-kappa B site downstream of the junB gene that mediates responsiveness to interleukin-6 in a murine plasmacytoma. J Biol Chem (1995) 1.03
Tumor necrosis factor alpha gene regulation: enhancement of C/EBPbeta-induced activation by c-Jun. Mol Cell Biol (1998) 1.02
Epidermal JunB represses G-CSF transcription and affects haematopoiesis and bone formation. Nat Cell Biol (2008) 1.01
Heterodimerization with Jun family members regulates c-Fos nucleocytoplasmic traffic. J Biol Chem (2007) 0.99
Dendritic cell biology. Adv Immunol (2005) 0.98
Nuclear factor kappaB inhibitors induce adhesion-dependent colon cancer apoptosis: implications for metastasis. Cancer Res (2002) 0.97
An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism. Cancer Res (2001) 0.97
Heterodimerization with different Jun proteins controls c-Fos intranuclear dynamics and distribution. J Biol Chem (2010) 0.96
JunB breakdown in mid-/late G2 is required for down-regulation of cyclin A2 levels and proper mitosis. Mol Cell Biol (2008) 0.93
Delayed wound healing and epidermal hyperproliferation in mice lacking JunB in the skin. J Invest Dermatol (2006) 0.90
Lipopolysaccharide up-regulates MHC class II expression on dendritic cells through an AP-1 enhancer without affecting the levels of CIITA. J Immunol (2007) 0.88
Differential activation profiles of multiple transcription factors during dendritic cell maturation. J Invest Dermatol (2005) 0.86
NF-kappaB elements contribute to junB inducibility by lipopolysaccharide in the murine macrophage cell line RAW264.7. FEBS Lett (2002) 0.82
JunB is required for IgE-mediated degranulation and cytokine release of mast cells. J Immunol (2007) 0.82
Lipopolysaccharide-induced desensitization of junB gene expression in a mouse macrophage-like cell line, P388D1. J Immunol (1998) 0.80
CNF1 exploits the ubiquitin-proteasome machinery to restrict Rho GTPase activation for bacterial host cell invasion. Cell (2002) 2.77
Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J Biol Chem (2005) 2.44
The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J Biol Chem (2003) 2.02
Ubiquitin-independent degradation of proteins by the proteasome. Biochim Biophys Acta (2008) 1.69
Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol (2005) 1.55
SUMO under stress. Biochem Soc Trans (2008) 1.47
SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1. J Cell Biol (2004) 1.24
Biomimetic divalent ligands for the acute disruption of synaptic AMPAR stabilization. Nat Chem Biol (2010) 1.18
Stable transmission of targeted gene modification using single-stranded oligonucleotides with flanking LNAs. Nucleic Acids Res (2005) 1.16
Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. Mol Cell Biol (2007) 1.16
c-Fos proto-oncoprotein is degraded by the proteasome independently of its own ubiquitinylation in vivo. Mol Cell Biol (2003) 1.06
The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene (2003) 1.04
SUMOylation regulates the transcriptional activity of JunB in T lymphocytes. J Immunol (2008) 1.03
The NF-κB member p65 controls glutamine metabolism through miR-23a. Int J Biochem Cell Biol (2012) 1.03
Heterodimerization with Jun family members regulates c-Fos nucleocytoplasmic traffic. J Biol Chem (2007) 0.99
Heterodimerization with different Jun proteins controls c-Fos intranuclear dynamics and distribution. J Biol Chem (2010) 0.96
Effects of virion surface gp120 density on infection by HIV-1 and viral production by infected cells. Virology (2005) 0.96
JunB breakdown in mid-/late G2 is required for down-regulation of cyclin A2 levels and proper mitosis. Mol Cell Biol (2008) 0.93
A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog (2010) 0.92
Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer? Biochimie (2007) 0.91
A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking. Mol Biol Cell (2008) 0.91
Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. Retrovirology (2014) 0.86
High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum Gene Ther (2002) 0.84
Efficient gene transfer into spleen cells of newborn mice by a replication-competent retroviral vector. Virology (2002) 0.84
Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genet Vaccines Ther (2004) 0.82
Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies. Blood (2012) 0.82
Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment. J Virol (2005) 0.82
Monoclonal antibody 667 recognizes the variable region A motif of the ecotropic retrovirus CasBrE envelope glycoprotein and inhibits Env binding to the viral receptor. J Virol (2003) 0.81
Protective effect of human endogenous retrovirus K dUTPase variants on psoriasis susceptibility. J Invest Dermatol (2012) 0.81
Fos family protein degradation by the proteasome. Biochem Soc Trans (2008) 0.80
Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol (2010) 0.80
Multiple degradation pathways for Fos family proteins. Ann N Y Acad Sci (2002) 0.80
Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice. J Virol (2007) 0.80
Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy? Crit Rev Oncol Hematol (2005) 0.79
The effects of N-terminal insertion into VSV-G of an scFv peptide. Virol J (2006) 0.79
The insertion of an anti-MHC I ScFv into the N-terminus of an ecotropic MLV glycoprotein does not alter its fusiogenic potential on murine cells. Virus Res (2002) 0.79
Efficient mother-to-child transfer of antiretroviral immunity in the context of preclinical monoclonal antibody-based immunotherapy. J Virol (2006) 0.79
Skin as a potential organ for ectopic monoclonal antibody production. J Invest Dermatol (2002) 0.78
In vivo infection of mice by replication-competent MLV-based retroviral vectors. Methods Mol Med (2003) 0.78
Monoclonal antibody-based genetic immunotherapy. Curr Gene Ther (2004) 0.77
Chromatin loop organization of the junb locus in mouse dendritic cells. Nucleic Acids Res (2013) 0.76
Diminished humoral responses against and reduced gene expression levels of human endogenous retrovirus-K (HERV-K) in psoriasis. J Transl Med (2014) 0.75
Evasion from proteasomal degradation by mutated Fos proteins expressed from FBJ-MSV and FBR-MSV osteosarcomatogenic retroviruses. Biochem Pharmacol (2002) 0.75
[Vaccine-like effects of antiviral monoclonal antibodies: a novel therapeutic perspective?]. Med Sci (Paris) (2013) 0.75
[Proteasomal degradation: from addressing of substrates to therapeutical perspectives]. Med Sci (Paris) (2005) 0.75